MIT Technology Review's conversation with the creator of AI-designed viruses sits at the difficult intersection of scientific progress, biosecurity, and publication norms.
AI can accelerate biological design, but the same acceleration makes safety boundaries harder to maintain. The problem is not whether science should proceed; it is how to share useful knowledge without lowering barriers to misuse.
This is where AI governance becomes domain-specific. Biology needs different disclosure rules, review processes, and institutional safeguards than consumer chatbots or coding tools.
Was this useful?
Help Pagish understand which AI stories are worth covering more deeply.
Tell Pagish if this story was useful.